Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Kempen Life Sciences Conference 2022
27 slides from Nykode Therapeutics Asa's conference presentation, Apr 20, 2022
Slide 1: Kempen Life Sciences conference
Kempen Life Sciences conference April 20, 2022
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today’s presenters from Nykode management
Today’s presenters from Nykode management International management team with solid drug development experience MICHAEL ENGSIG AGNETE B. FREDRIKSEN CEO Chief Innovation & Strategy Officer M.Sc. Biochemistry and G.D.Bus.Admin. M.Sc. in Molecular Biology and Ph.D. in Immunology Extensive experience fro
Slide 4: Overview
Overview Proprietary Vaccibody™ immunotherapy platform uniquely targets Antigen Presenting Cells (APCs) for a potent, broad and lasting immune response Pipeline of oncology and infectious disease vaccines includes partnered programs and wholly-owned clinical candidates Potentially more than $1
Slide 5: Top-tier collaborations for cancer and infectious disease vaccines valued potentially more than $1.64 billion
Top-tier collaborations for cancer and infectious disease vaccines valued potentially more than $1.64 billion plus royalties Partner Collaboration Terms Clinical Development $925M~ Regeneron to develop and potentially Multi-target license and $30M upfront commercialize products collaboration agree
Slide 6: Pipeline
Pipeline Discovery/ Upcoming Program Indication Phase 1 Phase 2 Phase 3 Partnerships Preclinical Milestones Nykode VB10.16 (off-the-shelf) HPV16+ cervical cancer3 3 1H22: Interim Data Oncology Internal (off-the-shelf) Undisclosed targets VB10.COV2 SARS-CoV-2 4 2H22: Interim Infectious data Disease I
Slide 7: Technology
a Ww Technology ac Va
Slide 8: Unique Antigen Presenting Cell (APC) targeted vaccine technology for cancer and infectious disease
Unique Antigen Presenting Cell (APC) targeted vaccine technology for cancer and infectious disease MODULAR VACCINE INCLUDES THREE DISTINCT COMPONENTS Vaccibody vaccines can be delivered through DNA, mRNA, viral vectors or as fusion protein DNA plasmid encoding Targeting unit to attract and bind APCs
Slide 9: Vaccine induces a rapid, robust and long-lasting CD8 T cell response against cancer cells
Vaccine induces a rapid, robust and long-lasting CD8 T cell response against cancer cells Nykode Therapeutics | Company Presentation | Non-confidential 9
Slide 10: CCL3L1 targeted Vaccibody induces effective cross-presentation resulting in broad, strong CD8 T cell responses
CCL3L1 targeted Vaccibody induces effective cross- presentation resulting in broad, strong CD8 T cell responses Pep 1 Pep 2 Pep 3 Pep 4 Pep 5 Pep 6 Pep 7 Pep 8 Pep 9 Pep10 Peptide* CD4 CD8 20µg d0, d20 10 peptides predicted to induce CD8 killer T cells 100µg/peptide RNA* CD4 (+poly I:C +50µg anti- C
Slide 11: Nykode’s modular platform enables generation of multiple specific and innovative products
Nykode’s modular platform enables generation of multiple specific and innovative products APC-specific Ag delivery and Expanded use of modularity stimulation Building additional Novel Infectious disease Cancer vaccines combinations and vaccines modules structures Vaccines against Novel therapeutics
Slide 12: Preclinical example data: 4th module GM-CSF
Preclinical example data: 4th module GM-CSF CT26 tumor model 10 µg dose GM: GM-CSF FL: FLT3L Nykode Therapeutics | Company Presentation | Confidential Poster presentation at AACR Annual meeting
Slide 13: VB10.NEO Overview
VB10.NEO Overview Nykode’s individualized cancer vaccine Nykode Therapeutics | Company Presentation | Non-confidential 13
Slide 14: VB10.NEO: Fully individualized neoantigen based cancer vaccine demonstrates strong, targeted immune response
VB10.NEO: Fully individualized neoantigen based cancer vaccine demonstrates strong, targeted immune response Finalized enrollment VB N-01; 5 indications, <50 pt VB10.NEO DATA Initiated VB N-02, in collaboration with Genentech; > 10 indications, 2 doses, combo with atezolizumab, ~40 patients De
Slide 15: VB10.16 Overview
VB10.16 Overview Nykode’s off the shelf vaccine targeting HPV16+ cancers Nykode Therapeutics | Company Presentation | Non-confidential 15
Slide 16: VB10.16: Therapeutic off-the-shelf HPV16 vaccine currently in Phase 2
VB10.16: Therapeutic off-the-shelf HPV16 vaccine currently in Phase 2 VB10.16 Finalized Phase I/IIa study with VB10.16 monotherapy in HPV16+ precancerous cervical lesions, VB C-01 Ongoing Phase II study of VB10.16 + atezolizumab in Targeting unit advanced cervical cancer, VB C-02 Dimerization un
Slide 17: VB10.16: Strong T cell responses with significant correlation to lesion size regression, VB C-01
VB10.16: Strong T cell responses with significant correlation to lesion size regression, VB C-01 STRONGHPV16-SPECIFIC T CELLREPSONSESIN ALL LESION SIZE REGRESSION CORRELATES PATIENTSIN THE EXPANSIONCOHORT WITH HPV-16 SPECIFIC RESPONSES All patients in the expansion cohort elicited a strong • Cohor
Slide 18: VB10.16: Strong additional clinical data as monotherapy in precancerous lesions, VB C-01
VB10.16: Strong additional clinical data as monotherapy in precancerous lesions, VB C-01 VB10.16 as a monotherapy in HPV16- LESION SIZE REDUCTION, CIN REGRESSION UPREGULATION OF PD-L1 IN RESPONSE TO positive, precancerous cervical AND HPV16 AND/OR P16 CLEARANCE VACCINATION Expansion Phase lesions in
Slide 19: VB10.16: Summary and next steps
VB10.16: Summary and next steps Finalized Phase I/IIa study with VB10.16 monotherapy in HPV16+ precancerous cervical lesions Demonstrated ability to induce strong HPV16 specific T cell responses Strong correlation between vaccine induced T cell responses and lesion size reduction Data from P
Slide 20: VB10.COV2
VB10.COV2 Nykode Therapeutics | Company Presentation | Non-confidential 20
Slide 21: Two COVID vaccine candidates currently in a Phase 1/2 study
Two COVID vaccine candidates currently in a Phase 1/2 study VB10.2210 – T CELL CANDIDATE VB10.2129 – RBD CANDIDATE T cell epitope vaccine inducing broadly RBD vaccine tailored to the B1.351 (Beta) protective T cell responses VoC to generate RBD-specific antibody and T cell immunity Targeting unit Ta
Slide 22: VB10.2210 includes a large set of conserved, validated T cell epitopes from 8 SARS-CoV-2 genes
VB10.2210 includes a large set of conserved, validated T cell epitopes from 8 SARS-CoV-2 genes • Nykode’s CCL3L1-targeting unit has shown to induce a differentiated T cell response, in particular broader CD8 T cell response 8 • T cells have an important role in controlling infectious diseases and Vi
Slide 23: Phase 1/2 trial investigating two candidates as a diverse booster in previously vaccinated subjects
Phase 1/2 trial investigating two candidates as a diverse booster in previously vaccinated subjects A Phase 1/2, open label, dose VB-D-01 TRIAL DESIGN escalation trial «RBD» CANDIDATE First subject with RBD Candidate 1: Healthy Cohort 1: Cohort 2: candidate dosed Nov. 3, 2021; volunteers first p
Slide 24: Financial overview
Financial overview Nykode Therapeutics | Company Presentation | Non-confidential 24
Slide 25: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision Financially well positioned to grow and execute the Company’s strategy over the next years Strong balance sheet YE 2021 liquidity of $228 mill Milestone payment of $20 mill for initiation of Phase 1b trial in 2H 2021 received 1Q 2022 Nykod
Slide 26: Expected near-term catalysts
Expected near-term catalysts 2022 Key Priorities Program Indication Partnerships Milestones (1H 2022) Wholly Owned Candidates* • Phase 2 interim data on 18 patients • Advance internal oncology VB10.16 programs including cervical HPV16+ cervical cancer (off the shelf) • Update on VB10.16 development
Slide 27: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Michael Engsig CEO IR@vaccibody.com Nykode Therapeutics | Company Presentation | Non-confidential
Nykode Therapeutics — Kempen Life Sciences Conference 2022 on 6ix